Core Viewpoint - The stock of Insilico Medicine (03696) surged nearly 15% in early trading, reaching a high of 54 HKD, which represents an increase of over 124% from its IPO price of 24.05 HKD [1] Group 1: Clinical Trials and Drug Development - Insilico Medicine announced the completion of the first dosing of its innovative PHD inhibitor ISM5411 in a Phase IIa clinical trial named BETHESDA [1] - The candidate drug, developed with the company's proprietary generative AI platform Pharma.AI, is designed for the treatment of inflammatory bowel disease (IBD) and has recently received official approval for its generic name Garutadustat from the USAN Council [1] Group 2: Strategic Partnerships - On January 5, Insilico Medicine announced a long-term collaboration with SIVAN to develop anti-tumor drugs, with a total collaboration amount of 888 million USD [1] - Insilico Medicine is eligible to receive up to 32 million USD in upfront payments and milestone payments for recent research developments [1] - The company will utilize its self-developed AI platform Pharma.AI to focus on challenging targets in the anti-tumor field, identifying and developing new therapeutic drugs, while SIVAN will co-share the research costs and lead subsequent clinical validation and commercialization processes [1]

Group 1 - Insilico Medicine announced a collaboration with Servier valued at $888 million focused on the discovery and development of innovative anti-cancer therapies [1] - Insilico will receive up to $32 million in upfront and milestone payments, leveraging its AI-driven drug development platform [1] - Servier will lead the clinical validation and commercialization of promising drug candidates globally [1] Group 2 - Weigao Blood Products announced a major asset restructuring involving the acquisition of 100% equity in Weigao Purui for approximately $8.511 billion [2] - Post-transaction, Weigao Purui will become a wholly-owned subsidiary, expanding the company's business into pharmaceutical packaging [2] - Weigao's shareholding in Weigao Blood Products will increase to 84.36%, maintaining absolute control [2] Group 3 - Earendil Labs (HuaShen ZhiYao) entered a strategic partnership with Sanofi worth up to $2.56 billion for the development of bispecific candidates targeting autoimmune and inflammatory diseases [3] - Earendil Labs will receive up to $160 million in upfront and milestone payments linked to early project outcomes [3] - The agreement includes tiered royalties based on net sales [3] Group 4 - WuXi AppTec announced that its controlling shareholders have reduced their stake by 2%, totaling 59.68 million shares [4] - The reduction was completed as per the previously disclosed plan, with the controlling shareholders holding 18.211% of the total shares before the reduction [4] Group 5 - Nanhua Biological announced plans for a significant asset restructuring to acquire 51% of Huize Pharmaceutical for cash [5] - The transaction is expected to constitute a major asset restructuring without involving share issuance or control changes [5] - Due diligence and negotiations are ongoing, with no formal agreement signed yet [5] Group 6 - Kangchen Pharmaceutical projected a net profit of between 145 million to 175 million yuan for 2025, representing a year-on-year increase of 243% to 315% [6] - The expected net profit excluding non-recurring gains is projected to be between 140 million to 170 million yuan, reflecting a significant increase from the previous year [6] Group 7 - Yilian Biotech signed a new exclusive licensing agreement with Roche for the YL201 project, with an upfront payment of $570 million [7] - The agreement allows Roche exclusive rights to develop and commercialize the YL201 project globally, excluding mainland China and certain regions [7] - This partnership builds on a successful collaboration on the YL211 project, aiming to accelerate the development of YL201 [7]

Core Insights - Insilico Medicine has entered a multi-year R&D collaboration with global pharmaceutical company Sihuiya, with a total agreement amount of up to $888 million [1] - The collaboration will leverage Insilico's AI platform Pharma.AI to develop challenging targets in the oncology field, with Insilico receiving up to $32 million in upfront and milestone payments [1] - Pharma.AI is a leading generative AI-driven drug discovery and development system that significantly enhances early-stage drug development efficiency, reducing the time from target discovery to preclinical candidate confirmation to 12-18 months compared to the traditional average of 4.5 years [1] Company Performance - Insilico has developed over 20 clinical/IND stage assets based on Pharma.AI, covering areas such as oncology, immunology, fibrosis, and metabolism [2] - The core self-developed product ISM001-055 for idiopathic pulmonary fibrosis has entered Phase II clinical trials, making it the fastest progressing AI drug globally [2] - Revenue from drug discovery and pipeline development is projected to be $28.648 million, $47.818 million, and $79.733 million from 2022 to 2024, accounting for over 90% of total revenue, while software sales remain below 10% [2] Financial Overview - Insilico's revenue from 2022 to the first half of 2025 is approximately $30.147 million, $51.180 million, $85.834 million, and $27.456 million, respectively [3] - Adjusted net losses during the same period were $70.804 million, $67.361 million, $22.665 million, and $15.409 million [3]

Core Viewpoint - The collaboration between 英硅智能 (03696.HK) and a global independent pharmaceutical company,施维雅, is valued at up to $888 million, focusing on the development of new cancer therapies using the company's AI platform, Pharma.AI [1] Group 1: Collaboration Details - The partnership is a multi-year research collaboration aimed at identifying and developing new therapeutic drugs targeting challenging oncology areas [1] - The agreement allows the company to receive up to $32 million in upfront and milestone payments for research [1] - The company will lead the discovery and development of potential drug candidates using its AI technology platform, while 施维雅 will share the R&D costs and lead subsequent clinical validation and commercialization processes [1]

Core Viewpoint - The collaboration between Insilico Medicine and a global independent pharmaceutical company, Sviat, is valued at up to $888 million, focusing on the development of new cancer therapies using Insilico's AI platform, Pharma.AI [1] Group 1: Collaboration Details - The partnership will leverage Insilico's AI technology to identify and develop new drug candidates targeting challenging oncology areas [1] - Insilico is eligible for an upfront payment of up to $32 million and milestone payments related to recent R&D achievements [1] - Sviat will share the R&D costs and lead the subsequent clinical validation and commercialization processes [1] Group 2: Statements from Executives - Christophe Thurieau, Executive Director at Sviat, emphasized the commitment to using advanced technology to address unmet medical needs and benefit patients [1] - Alex Zhavoronkov, CEO of Insilico, expressed excitement about the collaboration, highlighting the recognition of the company's AI drug development capabilities [1] - Zhavoronkov also mentioned the potential for generative AI to enhance drug development processes, making them faster, smarter, and safer [1]

Core Viewpoint - The collaboration between Insilico Medicine and a global independent pharmaceutical company, Sviat, is a significant multi-year R&D partnership valued at up to $888 million, focusing on challenging oncology targets and the development of new therapeutic drugs [1] Group 1: Partnership Details - The partnership will leverage Insilico's proprietary AI platform, Pharma.AI, to identify and develop potential drug candidates [1] - Insilico is eligible for an upfront payment of up to $32 million and milestone payments related to recent R&D achievements [1] - Sviat will co-fund the R&D costs and lead subsequent clinical validation and commercialization processes [1] Group 2: Statements from Executives - Christophe Thurieau, Executive Director at Sviat, emphasized the commitment to using cutting-edge technology to address unmet medical needs and benefit patients [1] - Alex Zhavoronkov, CEO of Insilico, expressed excitement about the collaboration, highlighting the recognition of the company's AI drug development capabilities and the potential for AI to enhance the drug development process [1]

格隆汇1月5日丨英矽智能(03696.HK)发布公告，集团已与一家由基金会管理的全球独立制药公司施维雅 达成多年期研发合作。该合作价值高达8.88亿美元，将充分利用集团自主研发的人工智能平台 Pharma.AI，聚焦于抗肿瘤领域具有挑战性的靶点，识别并开发全新的治疗药物。根据协议，集团将有 资格获得最高3,200万美元的首付款及近期研发里程碑付款，并将主导运用人工智能技术平台，发现及 开发符合既定标准的潜在候选药物，而施维雅将共同承担研发成本，主导后续临床验证及商业化进程。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 INSILICO MEDICINE InSilico Medicine Cayman TopCo 英矽智能 （於開曼群島註冊成立的有限公司） （股份代號：3696） 有關與施維雅達成多年期抗腫瘤藥物研發合作之自願公告 本公告乃由英矽智能（「本公司」，連同其附屬公司統稱「本集團」）自願作出。 英矽智能在人工智能驅動的腫瘤藥物研發方面擁有豐富經驗，公司已建立起覆 蓋多種癌症適應症、兼具中度新穎機制與成熟機制的腫瘤管線。其中，具潛力 成為同類最佳(best-in-class)療法的泛TEAD抑制劑ISM6331以及MAT2A抑制劑 ISM3412，均已啟動全球多中心I期臨床試驗。此外，公司還有四個腫瘤專案已全 部或部分對外授權予合作夥伴，相關I期臨床試驗正穩步推進中。 本公司謹此知會隨附新聞稿的本公司股東及潛在投資者，本集團已與一家由基金 會管理的全球獨立製藥公司施維雅達成多年期研發合作。該合作價值高達8.88 ...

来源：新浪证券 英矽智能本次IPO采用定价发行模式，发行价确定为24.05港元/股，基础发行股数约9469万股，绿鞋后 发行股数约1.09亿股，对应发行规模约22.8-26.2亿港元，资金将主要用于：1）关键临床阶段管线候选 药物的进一步临床研发；2）开发新的生成式AI模型及相关的验证研究工作；3）开发及扩展自动化实 验室；4）早期药物发现及开发等。 | 名称 | 上市日期 | 上市板 | 发行价格区间 (港元) | 碧资规模下限 (亿港元) | 葛资规模上限 (亿港元) | | --- | --- | --- | --- | --- | --- | | 英矽智能 | 2025-12-30 | 主板 | 24.05 | 22.8 | 26.2 | | 卧安机器人 | 2025-12-30 | 主板 | 63.00-81.00 | 14.0 | 20.7 | | 林清轩 | 2025-12-30 | 主板 | 77.77 | 10.9 | 12.5 | | 讯策 | 2025-12-30 | 主板 | 48.00-55.00 | 10.8 | 16.4 | | 五一视界 | 2025-12-30 | 主板 | ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 出品：新浪财经上市公司研究院 作者：喜乐 2025年12月18日，6家企业同步启动港股IPO流程，因发行至上市周期横跨圣诞节假期，6家公司均定于12月30日登陆港股主板，成为2025年最后一批港股 IPO上市项目。其中，全球AI驱动生物技术领域的代表性企业英矽智能，凭借超20亿港元的募资规模位列本批IPO发行规模之首。 英矽智能本次IPO采用定价发行模式，发行价确定为24.05港元/股，基础发行股数约9469万股，绿鞋后发行股数约1.09亿股，对应发行规模约22.8-26.2亿港 元，资金将主要用于：1）关键临床阶段管线候选药物的进一步临床研发；2）开发新的生成式AI模型及相关的验证研究工作；3）开发及扩展自动化实验 室；4）早期药物发现及开发等。 | 名称 | 下午日期 | 上市板 | 发行价格区间 (港元) | 墓资规模下限 (亿港元) | 墓资规模上限 (亿港元) | | --- | --- | --- | --- | --- | --- | | 英矽智能 | 2025-12-30 | 主板 | 24.05 | 22.8 | 26 ...